Xantinol nicotinate (Xantinol nicotinate)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceXantinol nicotinateXantinol nicotinate
Similar drugsTo uncover
  • Xantinol nicotinate
    solution w / m in / in 
    NOVOSIBHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
    BINNOFARM, CJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
    Armavir Biofactory, FKP     Russia
  • Xantinol nicotinate
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Xantinol nicotinate
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m 
    DALHIMFARM, OJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Xantinol nicotinate
    solution w / m in / in 
    ELLARA, LTD.     Russia
  • Xanthinal nicotinate-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
    • Dosage form: & nbspRAsterol for intravenous and intramuscular administration
    Composition:

    1 ml of the preparation contains:

    active substance: xanthinal nicotinate - 150.0 mg;

    auxiliary substance: water for injection - up to 1.0 ml.

    Description:Pa clear, colorless solution.
    Pharmacotherapeutic group:Vasodilator
    ATX: & nbsp

    C.04.A.D.02   Xantinol nicotinate

    Pharmacodynamics:

    Xanthinal nicotinate combines the properties of drugs of the theophylline and nicotinic acid group: it has antiaggregant effect, expands peripheral vessels, improves collateral circulation.Blocking adenosine receptors and phosphodiesterase, increases the content of cyclic adenosine monophosphate in the cell, substrate stimulates the synthesis of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADO). Improves microcirculation, oxygenation and nutrition of tissues. With prolonged use has antiatherosclerotic effect, activates the processes of fibrinolysis, lowers the concentration of cholesterol and atherogenic lipids, increases the activity of lipoprotein lipase, reduces the viscosity of blood, reduces the aggregation of platelets.

    Reducing the overall peripheral vascular resistance, contributes to an increase in the minute volume of blood and increased cerebral circulation, reduces the severity of cerebral hypoxia.

    Pharmacokinetics:

    The pharmacokinetics of xanthinal nicotinate is poorly understood. After intramuscular injection absorbed quickly and completely. With repeated use of the drug, its pharmacokinetics does not change. Cumulation of the drug is not noted.

    After administration, it undergoes intensive metabolism in the liver.In patients with impaired liver and kidney function, there was a slowing down of the elimination of xanthinal nicotinate and an increase in its bioavailability. A similar situation occurs in the elderly (over the age of 60), compared with young patients.
    Indications:

    In the complex therapy: obliterating atherosclerosis of the vessels of the extremities, Raynaud's disease, obliterating endarteritis, diabetic angiopathy, acute thrombophlebitis (of the superficial and deep veins), trophic ulcers of the shins, cerebrovascular insufficiency, cerebral artery atherosclerosis, cerebrovascular disease, coronary artery atherosclerosis, hypercholesterolemia, hypertriglyceridemia.

    Contraindications:

    Hypersensitivity to xanthinal nicotinate or any other component of the drug, acute heart failure or decompensated chronic heart failure, acute bleeding, acute myocardial infarction, mitral stenosis, peptic ulcer and duodenal ulcer in the exacerbation phase, arterial hypotension, pregnancy (especially in I trimester), lactation period, acute renal failure, glaucoma, unstable angina.

    Children's age (no experience is available).

    Pregnancy and lactation:

    Do not use in the first trimester of pregnancy. In the second and third trimester of pregnancy, the use of the drug is permissible only if there are absolute indications if the intended benefit to the mother exceeds the potential risk to the fetus. The use of the drug in this case should be done under close supervision of the doctor.

    If it is necessary to take the drug during lactation, breastfeeding should be interrupted. a nicotinic acid excreted in breast milk.

    Dosing and Administration:

    Intravenous (jet or drip), intramuscularly.

    The severity of the disease, the condition of the patient and the route of administration of the drug are evaluated by a doctor.

    With intramuscular injection - 2-6 ml of 15% solution daily for 2-3 weeks.

    The drug is injected intravenously slowly 300 mg (2 ml of the drug) 1-2 times a day (the patient should be in a horizontal position). The duration of treatment is 5-10 days.

    In acute violations of peripheral and cerebral circulation, the drug is administered intravenously drip at a rate of 40-50 drops per minute.To do this, 1500 mg (10 ml) of the drug is diluted in 200-500 ml of 5% solution of dextrose or in 200 ml of isotonic sodium chloride solution, the resulting infusion mixture is administered dropwise for 1,5-4 hours. Infusion can be repeated up to 4 times a day; the duration of treatment is 5 to 10 days.

    Patients with an implanted pacemaker are prescribed a lower dose.

    Side effects:

    From the side of the cardiovascular system: possible lowering blood pressure, dizziness, a feeling of heat, redness of the skin.

    From the digestive system: nausea, diarrhea, anorexia, gastralgia, abdominal pain, epigastric pain,

    From the nervous system: headache.

    Allergic reactions: itching, hives, angioedema, anaphylactic shock.

    Other: weakness, chills, tingling of the skin, especially in the head and neck. These symptoms usually disappear after 10-20 minutes, do not require special treatment and refusal to use this drug.

    When using drugs of nicotinic acid, a false increase in the concentration of catecholamines in blood and urine can be noted, and a false positive result of determining glucose in urine using a Benedict test can be noted.

    With long-term administration in high doses, the drug causes a change in glucose tolerance, an increase in the activity of "liver" transaminases (ACT, ALT) in the blood serum, an increase in the activity of alkaline phosphatase in the serum, an increase in the content of uric acid in the blood serum.

    If unwanted effects not described in this manual occur and if the above side effects are increased with this medication, tell your doctor immediately.

    Overdose:

    The drug is low toxicity. Acute overdose of xanthinal nicotinate is accompanied by arterial hypotension, general weakness, dizziness, tachycardia, abdominal pain and vomiting.

    When symptoms of an overdose appear symptomatic therapy.

    Interaction:

    To avoid a sharp decrease in blood pressure, the drug should not be used simultaneously with antihypertensive drugs, including (beta-blockers, alpha-blockers, ganglioblokatorov).

    Do not use simultaneously with monoamine oxidase inhibitors and strophanthin.

    Simultaneous use of nicotinic acid preparations in combination with inhibitors of HMG-CoA reductase (statins) may increase the risk of myopathy and rhabdomyolysis.

    Simultaneous use of alcohol can increase the severity of side effects of xanthinal nicotinate (sensation of heat, redness of the skin).

    Special instructions:

    In the second and third trimester of pregnancy and during lactation, the use of the drug is permissible only in the presence of absolute indications and careful observation of the doctor.

    Xanthinal nicotinate causes a "nicotine-like" syndrome, accompanied by hyperesthesia of the mucous membrane of the nasal cavity and mouth (exacerbates the sensitivity of the olfactory and taste buds). In this regard, the smell and taste of alcoholic beverages taken during therapy is perceived to be more abrupt and perverted.

    When diabetes is necessary to carefully monitor glycemia.

    Avoid contact with eyes or mucous membranes.
    Effect on the ability to drive transp. cf. and fur:

    Large doses of the drug may cause dizziness, weakness and arterial hypotension; therefore, one should refrain from driving a vehicle, working with mechanisms and engaging in other potentially dangerous activities requiring increased attention and speed of psychomotor reactions.

    Form release / dosage:

    Solution for intravenous and intramuscular injection, 150 mg / ml.

    Packaging:

    2 ml each in ampoules of neutral colorless glass.

    5 ampoules per contour cell packaging made of polyvinylchloride (PVC) film or polyethylene terephthalate (PET) film.

    For 1 or 2 contour packs with instructions for use and scarifier ampoule in a pack of cardboard.

    For 5 or 10 ampoules together with the instructions for use and scarifier ampoule in a pack of cardboard with a corrugated liner.

    When using ampoules with a dot or a ring of fracture, the ampoule scaper is not inserted.

    Packing for hospitals

    For 4, 5 or 10 contour mesh packages, together with the instructions for use in an amount equal to the number of contour mesh packages, into a pack of cardboard.

    For 50, 100 contour mesh packages together with the instructions for use in an amount equal to the number of contour mesh packages, into a box of corrugated cardboard.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003449
    Date of registration:04.02.2016
    Expiration Date:04.02.2021
    The owner of the registration certificate:ELLARA, LTD. ELLARA, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.01.2018
    Illustrated instructions
      Instructions
      Up